middle.news
Neurotech enters Phase III with NTI164 as funding focus sharpens
5:41pm on Monday 5th of October, 2026 AEDT
•
Biotechnology
Read Story
Neurotech enters Phase III with NTI164 as funding focus sharpens
5:41pm on Monday 5th of October, 2026 AEDT
Key Points
Beyond Harmony Phase III trial initiated at Monash Children’s Hospital
150 children planned for enrolment in paediatric ASD study
FY2026 net loss narrowed to $6.54 million
Cash fell to $2.39 million while operating outflow reached $4.22 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE